212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement

Psoriatic Arthritis ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.1575 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 730.2-730 ◽

Author(s):

A. Adebajo ◽

A. Wells ◽

C. Edwards ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

214. Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis and Current Skin Involvement: Results of Palace 3, a Phase 3, Randomized, Controlled Trial

Rheumatology ◽

10.1093/rheumatology/keu115.008 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i139-i140 ◽

Cited By ~ 2

Author(s):

Christopher J. Edwards ◽

Francisco J. Blanco ◽

Jeffrey Crowley ◽

ChiaChi Hu ◽

Randall M. Stevens ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2013-eular.309 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A85.3-A86 ◽

Cited By ~ 4

Author(s):

C. Birbara ◽

F. J. Blanco ◽

J. J. Crowley ◽

C. Hu ◽

R. Stevens ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

10.1136/annrheumdis-2014-eular.1096 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 732.1-732 ◽

Author(s):

A. Wells ◽

C. Edwards ◽

A.O. Adebajo ◽

A.J. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.1574 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 735.1-735 ◽

Cited By ~ 5

Author(s):

C. Edwards ◽

A. Wells ◽

A. Adebajo ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2013-eular.2005 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A678.1-A678 ◽

Author(s):

C. Birbara ◽

F. J. Blanco ◽

J. J. Crowley ◽

C. Hu ◽

R. Stevens ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.4419 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 736.1-736 ◽

Author(s):

F. Zhang ◽

T. Tencer ◽

S. Li

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Work Productivity ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

10.1136/annrheumdis-2014-eular.3878 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 739.4-740 ◽

Author(s):

P. Schafer ◽

P. Chen ◽

L. Fang ◽

A. Wang ◽

R. Chopra

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

10.1136/annrheumdis-2015-eular.2889 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 348.2-349 ◽

Cited By ~ 3

Author(s):

C. Edwards ◽

F. Blanco ◽

J. Crowley ◽

C. Hu ◽

K. Shah ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽